ArticleAmerican journal of translational research2025
Anticancer activity of
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Escherichia coli DH5α-loaded fenugreek extract: an effective anticancer combination against human breast cancer cell lines.Applied microbiology and biotechnology · 2026Article
- Fenugreek seed extract-doxorubicin synergy against hepatocellular carcinoma in HepG2 cells: in vitro and in silico mechanistic studies.BMC complementary medicine and therapies · 2026Article
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.Cancers · 2026Review
- Phytochemical evaluation, nutritional and pharmacological values ofFrontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimPancreatic cancer exhibits resistance to currently available drugs in the pharmaceutical industry. The development of new drugs is crucial, and research on plant substances with biological activities against cancer is actively underway. This study explored the potential use of fenugreek seed extract (FSE) in pancreatic cancer treatment as the anticancer activity of FSE is still poorly understood. MATERIALS AND
methodsThe anticancer activity of FSE on pancreatic cancer cells was evaluated using cell viability and apoptosis assays. The migration rate of cancer cells was quantified using wound healing and Transwell migration assays. Western blotting was utilized to assess relevant signaling pathways, and LC-MS/MS was employed to detect the active compounds in FSE.
resultsFSE inhibited the proliferation of pancreatic cancer cell lines (Panc-1, Miapaca-2, SNU-213, and Aspc-1) in a time and dose-dependent manner without greatly affecting normal cells (293T). The inhibition of cancer cell proliferation was attributed to the activation of cleaved caspase-3 and Bax, a pro-apoptotic marker. The anticancer effects and inhibition of cell migration were mediated by the MAPK, Akt, MMP-9, and vimentin signaling pathways through inactivation of the phosphorylated proteins related to cell growth, differentiation, and migration. LC-MS/MS analysis detected various active compounds capable of inducing apoptosis in pancreatic cancer cells.
conclusionWe demonstrated that FSE has anticancer properties by inducing apoptosis and preventing metastasis in pancreatic cancer cells without affecting normal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.